Friday, 15 September 2017 - Radebeul, Germany & Lyon, France, September 15 , 2017 --
RIBOXX PHARMACEUTICALS, a
biotech
company
developing
Toll-like-receptor
(TLR) and RIG-I-
like
-
Receptor
(RLR) ligands, and ACCINOV, a
pharmaceutical
establishment for
experimental
drug
products
,
today
announced
the
successful
industrial
GMP
manufacturing
,
including
packaging and
quality
control of RIBOXXIM®, a
novel
and
highly
potent
Toll-like

Receptor
3 (TLR
3)-
ligand.

Manufacturing has been performed with the patented process TENPORA® of RIBOXX in full compliance
with
the EU GMP
requirements
, and
with
the GMP
specifica
tions
of the
experimental
drug
.

RIBOXXIM® is a proprietary drug substance of RIBOXX PHARMACEUTICALS. It activates the innate immune system to eliminat
e cancer
cells
as a
validated
approach
in
immuno-oncology
with
the
historical
TLR3 ligand
poly(
I:

C) and its derivatives.

RIBOXXIM® has been validated in multiple pre-clinical studies for immunotherapy of cancer. It displays unique physico-chemical and biological properties, as well as optimal biodisponibility with increased stability to degradation in body fluids such as human plasma. RIBOXXIM® is stable as a drug product in liquid form for several months

.

Prof. Dr. Jacques Rohayem, CEO and CSO of RIBOXX PHARMACEUTICALS de
clared
:
"
We
are
proud
to have
reached
this
important
milestone
in the
development
of TLR3 ligands,
with
a unique,
highly
potent
and stable
drug
product
as a
better
alternative to poly(I:C) and
its
derivatives
. RIBOXXIM®
is
available
for
pharmaceuticals
companies
or
universities

developing
clinical
applications in
immuno-onco
logy
and
therapeutic
vaccines."

André Dupont, President of ACCINOV declared: "We are proud to be the
manufacturer of
this
innovative
experimental
drug
. This
achievement
demonstrates
the high
flexibility
of the ACCINOV model."